You are leaving the Blue Earth Therapeutics website. By clicking this link, you will be taken to a website that is independent from Blue Earth Therapeutics. The site you are linking to is not controlled or endorsed by Blue Earth Therapeutics and Blue Earth Therapeutics is not responsible for the content provided on that site.
PIPELINE
Blue Earth Therapeutics is developing next generation targeted radiotherapeutics to transform the clinical management of patients with cancer.
The company has acquired exclusive worldwide rights to radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) targeted technology for therapeutic use and has a research programme initially focused on prostate cancer. The rhPSMA molecule is being investigated in two programmes; one using the beta emitting radioisotope lutetium 177 (177Lu), and one using the alpha emitter actinium 225 (225Ac).
OUR PIPELINE
Blue Earth Therapeutics is investigating the use of the rhPSMA molecule for therapy with the addition of an alpha or beta emitting radioisotope.
177Lu-rhPSMA-10.1 is currently being studied to evaluate its safety profile, tolerability, radiation dosimetry and anti-tumour activity in men with metastatic castrate-resistant prostate cancer (NCT05413850).
https://www.clinicaltrials.gov/ct2/show/NCT05413850?term=NCT05413850
PP-UK-0650 / October 2023
Contact Us
Magdalen Centre
Robert Robinson Avenue
The Oxford Science Park, Oxford
OX4 4GA, UK
